bo-112
Nucleic acidexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02828098)
Timeline
Indications
Mechanism of action
- Toll-like receptor 3ACTIVATOR
TLR3 activator
IFIH1 activator
PLAAT4 activator
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bo-112
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06422936 | Phase 2 | May 27, 2024 | Highlight Therapeutics |
| NCT05265650 | Phase 1/Phase 2 (Phase 2) | Jun 13, 2022 | Clinica Universidad de Navarra, Highlight Therapeutics |
| NCT04777708 | Early Phase 1 (Phase 1) | Oct 13, 2021 | Highlight Therapeutics, Merck, University of California, Los Angeles |
| NCT04570332 | Phase 2 | Dec 14, 2020 | Highlight Therapeutics |
| NCT04508140 | Phase 2 | Jun 17, 2020 | Highlight Therapeutics |
| NCT02828098 | Phase 1 | Jun 1, 2016 | Bioncotech Therapeutics |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Highlight Therapeutics | For profit | 5 | 3 | 2 | 2020 |
| Bioncotech Therapeutics | For profit | 1 | 1 | 1 | 2016 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1